Bromfenac (Duract)-associated hepatic failure requiring liver transplantation.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 10445569.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bromfenac sodium (Duract) is a phenylacetic acid-derived nonsteroidal anti-inflammatory agent introduced in the United States in 1997 and withdrawn in 1998. We describe the first case of fulminant hepatic failure associated with this agent treated successfully with liver transplantation. Similarities to hepatotoxicity with related agents is discussed.
Medical subject headings
- Anti-Inflammatory Agents, Non-Steroidal
- Benzophenones
- Bromobenzenes
- Liver Failure
- Liver Transplantation
- Osteoarthritis